{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:14:17Z","timestamp":1793826857282,"version":"4.6.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NIH","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"NIH","award":["K07 CA166210"],"award-info":[{"award-number":["K07 CA166210"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.ygyno.2016.05.022","type":"journal-article","created":{"date-parts":[[2016,8,10]],"date-time":"2016-08-10T10:51:45Z","timestamp":1470826305000},"page":"3-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":236,"title":["Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline"],"prefix":"10.1016","volume":"143","author":[{"given":"Alexi A.","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Bohlke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah K.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Bookman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Cliby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don S.","family":"Dizon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Kash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa A.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander B.","family":"Olawaiye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Oldham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Salani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee","family":"Sparacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Tew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell I.","family":"Edelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2016.05.022_bb0005","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0010","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2016.05.022_bb0015","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0140-6736(14)62259-5","article-title":"Neoadjuvant chemotherapy for ovarian cancer: do we have enough evidence?","volume":"386","author":"Kang","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2016.05.022_bb0020","series-title":"Proceedings Society of Gynecologic Oncology Annual Meeting on Women's Cancer","article-title":"Phase III SCORPION trial (ID number: NCT01461850) in epithelial cancer patients with high tumor load receiving PDS versus NACT: an interim analysis on peri-operative outcome","author":"Fagotti","year":"2015"},{"issue":"5s","key":"10.1016\/j.ygyno.2016.05.022_bb0025","article-title":"Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III\/IV ovarian, tubal, and peritoneal cancers in phase III randomized trial: JCOG0602","volume":"32","author":"Onda","year":"2014","journal-title":"J. Clin Oncol"},{"key":"10.1016\/j.ygyno.2016.05.022_bb0030","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1016\/j.ejca.2013.06.013","article-title":"Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial","volume":"49","author":"van Meurs","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2016.05.022_bb0035","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ygyno.2007.05.032","article-title":"A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model","volume":"107","author":"Aletti","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0040","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1200\/JCO.2006.07.7800","article-title":"Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer","volume":"25","author":"Axtell","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0045","doi-asserted-by":"crossref","first-page":"462.e1-11","DOI":"10.1016\/j.ajog.2013.07.016","article-title":"A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer","volume":"209","author":"Fagotti","year":"2013","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0050","first-page":"4043","article-title":"Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer","volume":"31","author":"Gerestein","year":"2011","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0055","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2014.07.002","article-title":"A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer","volume":"134","author":"Suidan","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0060","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/AOG.0b013e31822a6d56","article-title":"Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly","volume":"118","author":"Thrall","year":"2011","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0065","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Winter","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0070","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ygyno.2011.08.027","article-title":"Defining the limits of radical cytoreductive surgery for ovarian cancer","volume":"123","author":"Wright","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0075","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","article-title":"Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma","volume":"33","author":"Bohm","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0080","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ygyno.2013.08.005","article-title":"Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience","volume":"131","author":"Fagotti","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0085","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ygyno.2013.08.023","article-title":"A prospective comparison of integrated FDG-PET\/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer","volume":"131","author":"Hynninen","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0090","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00330-013-3083-8","article-title":"Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET\/CT","volume":"24","author":"Michielsen","year":"2014","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0095","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jso.21398","article-title":"Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis","volume":"101","author":"Kang","year":"2010","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0100","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1097\/01.AOG.0000265207.27755.28","article-title":"Influence of the gynecologic oncologist on the survival of ovarian cancer patients","volume":"109","author":"Chan","year":"2007","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0105","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/jnci\/djj019","article-title":"Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients","volume":"98","author":"Earle","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0110","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ygyno.2006.08.010","article-title":"Ovarian cancer: patterns of surgical care across the United States","volume":"103","author":"Goff","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0115","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jamcollsurg.2015.01.056","article-title":"Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival","volume":"220","author":"Bristow","year":"2015","journal-title":"J. Am. Coll. Surg."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0120","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ygyno.2009.08.025","article-title":"Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes","volume":"115","author":"Bristow","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ygyno.2014.10.023","article-title":"Ovarian cancer in the United States: contemporary patterns of care associated with improved survival","volume":"136","author":"Cliby","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0130","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2008.11.011","article-title":"Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands","volume":"112","author":"Vernooij","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0135","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.critrevonc.2007.11.001","article-title":"Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study","volume":"65","author":"Audisio","year":"2008","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0140","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/cncr.21422","article-title":"Developing a cancer-specific geriatric assessment: a feasibility study","volume":"104","author":"Hurria","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2016.05.022_bb0145","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ygyno.2016.02.015","article-title":"Evaluation of the performance of the ACS NSQIP surgical risk calculator in gynecologic oncology patients undergoing laparotomy","volume":"141","author":"Rivard","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007565.pub2","article-title":"Optimal primary surgical treatment for advanced epithelial ovarian cancer","author":"Elattar","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0155","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0160","series-title":"International Meeting of the European Society of Gynaecological Oncology","article-title":"Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer (LapOvCa): a multicentre randomised controlled trial, ESGO19","author":"Buist","year":"2015"},{"key":"10.1016\/j.ygyno.2016.05.022_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009786.pub2","article-title":"Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer","volume":"2","author":"Rutten","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0170","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","article-title":"Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome","volume":"59","author":"Fagotti","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2016.05.022_bb0175","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0180","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0185","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ygyno.2011.08.030","article-title":"Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer","volume":"123","author":"Thrall","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0190","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/cncr.28508","article-title":"Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer","volume":"120","author":"Wright","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2016.05.022_bb0195","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ygyno.2013.05.040","article-title":"Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis","volume":"130","author":"Chang","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0200","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0210","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0220","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0225","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0230","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0235","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0240","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ygyno.2008.10.028","article-title":"Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009","volume":"112","author":"Tiersten","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0245","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3747\/co.v18i2.725","article-title":"Phase ii\/iii study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: ncic ctg ov.21.","volume":"18","author":"Mackay","year":"2011","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0250","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.18_suppl.LBA5503","article-title":"OV21\/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC)","volume":"34","author":"Mackay","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0255","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0260","series-title":"ASCO Educational Book","first-page":"442","article-title":"The power of words: discussing decision making and prognosis","author":"Dizon","year":"2013"},{"key":"10.1016\/j.ygyno.2016.05.022_bb0265","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ygyno.2014.10.028","article-title":"Treatment of ovarian cancer in the older woman","volume":"136","author":"Tew","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0270","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ygyno.2015.03.050","article-title":"Costs of treatment for elderly women with advanced ovarian cancer in a Medicare population","volume":"137","author":"Forde","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"763","key":"10.1016\/j.ygyno.2016.05.022_bb0275","first-page":"e1","article-title":"Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65years old or older","volume":"212","author":"Rowland","year":"2015","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2016.05.022_bb0280","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2015.10.025","article-title":"Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer","volume":"140","author":"Kumar","year":"2016","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581630751X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581630751X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,9]],"date-time":"2018-09-09T09:27:14Z","timestamp":1536485234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581630751X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S009082581630751X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.05.022","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Society of Gynecologic Oncology and American Society of Clinical Oncology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}